JP2010538020A5 - - Google Patents

Download PDF

Info

Publication number
JP2010538020A5
JP2010538020A5 JP2010523239A JP2010523239A JP2010538020A5 JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5 JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010523239 A JP2010523239 A JP 2010523239A JP 2010538020 A5 JP2010538020 A5 JP 2010538020A5
Authority
JP
Japan
Prior art keywords
protein
crystallin
fragment
composition
angiogenic fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010523239A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010538020A (ja
JP5685773B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/AU2008/001319 external-priority patent/WO2009029991A1/en
Publication of JP2010538020A publication Critical patent/JP2010538020A/ja
Publication of JP2010538020A5 publication Critical patent/JP2010538020A5/ja
Application granted granted Critical
Publication of JP5685773B2 publication Critical patent/JP5685773B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010523239A 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤 Expired - Fee Related JP5685773B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2007904857A AU2007904857A0 (en) 2007-09-07 Agents with angiogenic and wound healing activity
AU2007904857 2007-09-07
PCT/AU2008/001319 WO2009029991A1 (en) 2007-09-07 2008-09-05 Agents with angiogenic and wound healing activity

Publications (3)

Publication Number Publication Date
JP2010538020A JP2010538020A (ja) 2010-12-09
JP2010538020A5 true JP2010538020A5 (enExample) 2011-10-20
JP5685773B2 JP5685773B2 (ja) 2015-03-18

Family

ID=40428369

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010523239A Expired - Fee Related JP5685773B2 (ja) 2007-09-07 2008-09-05 血管新生および創傷治癒活性がある薬剤

Country Status (6)

Country Link
US (1) US8404644B2 (enExample)
EP (2) EP2190455A4 (enExample)
JP (1) JP5685773B2 (enExample)
AU (1) AU2008295449A1 (enExample)
NZ (1) NZ583803A (enExample)
WO (1) WO2009029991A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009029991A1 (en) * 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity
US8758802B2 (en) 2009-12-14 2014-06-24 University Of Massachusetts Methods of inhibiting cataracts and presbyopia
CA2823505A1 (en) * 2011-01-26 2012-08-02 Megmilk Snow Brand Co., Ltd. Agent for improving peripheral sensitivity of skin
WO2013073968A2 (en) * 2011-09-12 2013-05-23 Industrial Research Limited Agents for modulation of cell signalling
JP2014005254A (ja) * 2012-06-26 2014-01-16 Bfsr:Kk 熱傷由来全身性炎症反応症候群の予防外用薬
SG11201507209SA (en) 2013-03-14 2015-10-29 Univ Massachusetts Methods of inhibiting cataracts and presbyopia
KR20170040648A (ko) * 2015-10-05 2017-04-13 차의과학대학교 산학협력단 당뇨병성 족부궤양의 예방 또는 치료용 약학 조성물
SG11201803606XA (en) 2015-11-13 2018-05-30 Univ Massachusetts Bifunctional molecules containing peg for use in inhibiting cataracts and presbyopia
JP2022522247A (ja) * 2019-02-08 2022-04-14 オークランド ユニサービシズ リミテッド 生体材料およびそれに関連する方法

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2187482A1 (en) * 1995-10-13 1997-04-14 Eri Inoue Pharmaceutical composition
WO1999051634A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-3
WO1999051738A1 (en) 1998-04-03 1999-10-14 Hunan Medical University Human gap junction protein beta-4
AU6290299A (en) 1998-10-15 2000-05-01 E.I. Du Pont De Nemours And Company Polymers, containing a fluorocyclobutyl ring and their preparation
WO2004005883A2 (en) 2002-07-02 2004-01-15 The Johns Hopkins University Secreted and cytoplasmic tumor endothelial markers
JP3783200B2 (ja) * 2000-08-24 2006-06-07 株式会社加美乃素本舗 血管新生剤
US7263214B2 (en) 2002-05-15 2007-08-28 Ge Medical Systems Global Technology Company Llc Computer aided diagnosis from multiple energy images
US20030215424A1 (en) 2002-05-15 2003-11-20 Seul Kyung Hwan Method of modulating angiogenesis
JPWO2004096277A1 (ja) 2003-05-01 2006-07-13 国立大学法人京都大学 眼内血管新生疾患の予防又は治療剤
WO2005004894A2 (en) 2003-05-12 2005-01-20 Expressive Constructs, Inc. Methods for increasing cell and tissue viability
US7456151B2 (en) * 2004-07-14 2008-11-25 University Of Utah Research Foundation Promoting angiogenesis with netrin1 polypeptides
KR101840445B1 (ko) 2005-02-03 2018-05-04 코다 테라퓨틱스 (엔지) 리미티드 항-코넥신 화합물 및 그의 용도
US7897581B2 (en) 2005-02-24 2011-03-01 Massachusetts Eye & Ear Infirmary Methods and compounds for promoting vessel regression
WO2007084895A2 (en) 2006-01-13 2007-07-26 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
US20100004168A1 (en) * 2006-06-30 2010-01-07 The Johns Hopkins University Use of Crystallin For The Modulation of Angiogenesis
CN101965193A (zh) 2006-11-15 2011-02-02 科达治疗公司 用于伤口愈合的改进方法和组合物
EP2104511A4 (en) 2006-12-11 2010-06-09 Univ Leland Stanford Junior ALPHA-B-CRYSTALLINE AS THERAPY AGAINST INFLAMMATION
WO2009012224A2 (en) 2007-07-13 2009-01-22 The Research Foundation Of State University Of New York Peptide-based regulation of gap junctions
WO2009029991A1 (en) * 2007-09-07 2009-03-12 Meat & Livestock Australia Limited Agents with angiogenic and wound healing activity

Similar Documents

Publication Publication Date Title
JP2010538020A5 (enExample)
JP2014530220A5 (enExample)
JP2010222367A5 (enExample)
CL2008002411A1 (es) Compuestos derivados de heterociclos de nitrogenos;composicion farmaceutica que comprende a dichos compuestos; y su uso en el tratamiento de una enfermedad asociada con la miosina del musculo liso o la miosina no muscular, tales como hipertension, enfermedad pulmonar, glaucoma, apoplejia, enfermedades broncocontrictoras, entre otras.
JP2012041342A5 (enExample)
CL2008000690A1 (es) Compuestos derivados del acido indol-3-propionico; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hiperlipidemia, hipertension; entre otras.
CL2008001125A1 (es) Compuestos derivados de pirimidinona condensada con heterociclos; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como diabetes, sindrome metabolico y obesidad.
JP2013155188A5 (enExample)
CL2007002689A1 (es) Compuestos derivados de piperidin-1-carboxamida, inhibidores de la renina; compuestos intermediarios; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como hipertension, insuficiencia cardiaca, fibrosis cardiaca, entre otras.
WO2009154840A3 (en) Compositions and methods using stem cells in cutaneous wound healing
NO20084187L (no) Medikamenter og proteiner
WO2009142772A3 (en) Methods and treatment for allergies and inflammation associated with gastrointestinal diseases
CL2012003038A1 (es) Polietilenglicol conjugado a factor viia; composicion farmacéutica que comprende dicho polietilenglicol conjugado a factor viia; uso de una composicion farmaceutica para tratar enfermedad o trauma de la coagulacion de la sangre en un paciente que la necesita; proceso para preparar el siguiente polietilenglicol conjugado a factor viia.
CR10166A (es) Uso de derivados de sulfamida heterociclo benzo-fusionado para el tratamiento del trastorno bipolar y mania
CO6640218A2 (es) Heterociclilbencillporazoles sustituidos y uso de los mismos
CO7310526A2 (es) Composición farmaceútica oral en forma de microesferas y proceso de elaboración
NZ583803A (en) Agents with angiogenic and wound healing activity
CU20160088A7 (es) Piperidinil-tetrahidroquinolinas sustituidas
PH12014501579A1 (en) Combination of beta-hydroxy-beta-methylbutyrate, arginine and glutamine for use in treating diabetic ulcers
BR0009186A (pt) Sais de ácidos asiático e madecássico adequados para preparação de composições farmacêuticas e cosméticas
AR072951A1 (es) Uso de dronedarona o una sal aceptable farmaceuticamente de esta, para la preparacion de un medicamento para regular el nivel de potasio en la sangre
UY28953A1 (es) Derivados heterocíclicos para el tratamiento de hiperlipidemia y enfermedades relacionadas
SV2010003578A (es) Oxazolidinonas para el tratamiento y profilaxis de la insuficiencia cardiaca
JP2017513944A5 (enExample)
EA201071138A1 (ru) Применение дронедарона для получения лекарственного средства для лечения пациентов с аритмией и с повышенным уровнем креатинина в результате введения дронедарона